Patient-Derived Xenografts and Organoids Recapitulate Castration-Resistant Prostate Cancer with Sustained Androgen Receptor Signaling

Patient-Derived Xenografts and Organoids Recapitulate Castration-Resistant Prostate Cancer with Sustained Androgen Receptor Signaling

Castration-resistant prostate cancer (CRPC) remains an incurable and lethal malignancy. The development of new CRPC treatment strategies is strongly impeded by the scarcity of representative, scalable and transferable preclinical models of advanced, androgen receptor (AR)-driven CRPC. Here, we prese...

Full description

Bibliographic Details
Main Authors: Annelies Van Hemelryk, Ingrid Tomljanovic, Corrina M. A. de Ridder, Debra C. Stuurman, Wilma J. Teubel, Sigrun Erkens-Schulze, Esther I. Verhoef, Sebastiaan Remmers, Amrish J. Mahes, Geert J. L. H. van Leenders, Martin E. van Royen, Harmen J. G. van de Werken, Magda Grudniewska, Guido W. Jenster, Wytske M. van Weerden
Format: Article
Language:English
Published: MDPI AG 2022-11-01
Series:Cells
Subjects:
castration-resistant prostate cancer
patient-derived xenografts
organoids
androgen receptor
drug testing
Online Access:https://www.mdpi.com/2073-4409/11/22/3632

Internet

https://www.mdpi.com/2073-4409/11/22/3632

Similar Items